Phil Sarocco, Head of Health Economics, Shire
Phil Sarocco is a Pharmaceutical and Medical Device executive with 23 years of work experience in global pharmaceutical health economics/outcomes research, managed care marketing as well as expertise in R&D, medical device health economics and reimbursement. Started his career in Health Economics/Outcomes Research (HEOR) in 1994 in Pﬁzer’s Global Pharmaceuticals Group. He then was offered the opportunity to build out the HEOR team at Warner Lambert, launching Lipitor during this period. Subsequently went onto start and build the US HEOR team at the then newly formed Aventis Pharma in 2000. After the merger of Sanoﬁ and Aventis, Phil created and led a ﬁeld-based HEOR Medical Liaison team at Sanoﬁ -Aventis. He then moved to build out the HEOR function at Sepracor Pharmaceuticals. Phil was recruited in 2011 to start and build out and lead the HEOR function at a small biotech start-up company, Ironwood Pharmaceuticals, based in Cambridge, MA. After Ironwood, Phil formed his own consultancy ‘Value in Healthcare’. His client work included strategic and tactical consulting in HEOR, Market Access, and public payer policy and evidence generation for start- up, small to medium sized life science based companies in the US and the EU. In 2015, he joined the global HEOR team in Shire, with genetic therapy and enzyme therapies for several rare/orphan diseases as well as CNS and Ophthalmic. Currently, Phil is building out the global HEOR function for a pre-commercial start up Cytokinetics in the areas of rare disease such as ALS, SMA, and others.
Undergraduate training in Biochemistry, professional training and work experience in Clinical Pharmacy in pediatric and home health pharmacy. He holds a professional degree in Pharmacy degree from Massachusetts College of Pharmacy. He received his Masters of Science degree in Public Health/Decision Management Sciences from Harvard University.